IA
PACB icon

IFP Advisors’s Pacific Biosciences PACB Stock Holding History

IFP Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Sell
18,609
-16,097
-46% -$23.4K ﹤0.01% 2695
2026
Q1 		$45.8K Sell
34,706
-18,081
-34% -$32.3K ﹤0.01% 2300
2025
Q4 		$98.7K Sell
52,787
-42,825
-45% -$82.3K ﹤0.01% 1798
2025
Q3 		$122K Sell
95,612
-52,718
-36% -$71.4K ﹤0.01% 1558
2025
Q2 		$184K Sell
148,330
-45,950
-24% -$53.1K 0.01% 1307
2025
Q1 		$229K Sell
194,280
-7,305
-4% -$11.2K 0.01% 1112
2024
Q4 		$369K Buy
201,585
+38,984
+24% +$76.1K 0.01% 861
2024
Q3 		$276K Buy
162,601
+161,601
+16,160% +$266K 0.01% 933
2024
Q2 		$1.37K Hold
1,000
– – ﹤0.01% 2910
2024
Q1 		$3.75K Hold
1,000
– – ﹤0.01% 2534
2023
Q4 		$9.81K Hold
1,000
– – ﹤0.01% 2193
2023
Q3 		$8.35K Sell
1,000
-250
-20% -$2.86K ﹤0.01% 2326
2023
Q2 		$16.6K Hold
1,250
– – ﹤0.01% 2100
2023
Q1 		$3.26K Sell
1,250
-1,600
-56% -$15.9K ﹤0.01% 2734
2022
Q4 		$8K Sell
2,850
-300
-10% -$2.58K ﹤0.01% 3543
2022
Q3 		$9K Hold
3,150
– – ﹤0.01% 3724
2022
Q2 		$9K Hold
3,150
– – ﹤0.01% 3476
2022
Q1 		$9K Hold
3,150
– – ﹤0.01% 3476
2021
Q4 		$63K Sell
3,150
-450
-13% -$10.9K ﹤0.01% 1474
2021
Q3 		$92K Buy
3,600
+50
+1% +$1.48K ﹤0.01% 1330
2021
Q2 		$124K Buy
3,550
+500
+16% +$14.5K ﹤0.01% 1136
2021
Q1 		$102K Sell
3,050
-7,950
-72% -$278K ﹤0.01% 1169
2020
Q4 		$286K Buy
11,000
+1,000
+10% +$17K 0.01% 678
2020
Q3 		$99K Buy
10,000
+5,000
+100% +$28.8K 0.01% 1005
2020
Q2 		$17K Sell
5,000
-37
-0.7% -$126 ﹤0.01% 1613
2020
Q1 		$18K Buy
5,037
+5,000
+13,514% +$20.5K ﹤0.01% 1535
2019
Q4 		$0 Sell
37
-200
-84% -$1.02K ﹤0.01% 3034
2019
Q3 		$1K Buy
+237
New +$1.33K ﹤0.01% 2904
2019
Q1 		$108K Sell
15,000
-8,196
-35% -$59.3K 0.01% 663
2018
Q4 		$170K Sell
23,196
-17,693
-43% -$112K 0.01% 930
2018
Q3 		$221K Buy
40,889
+1,050
+3% +$4.5K 0.01% 1024
2018
Q2 		$141K Sell
39,839
-16,945
-30% -$47K 0.01% 1285
2018
Q1 		$150K Hold
56,784
– – 0.01% 1131
2017
Q4 		$150K Sell
56,784
-450
-0.8% -$1.58K 0.01% 1137
2017
Q3 		$300K Sell
57,234
-550
-1% -$2.36K 0.01% 924
2017
Q2 		$206K Sell
57,784
-10,398
-15% -$41.9K 0.01% 1112
2017
Q1 		$353K Sell
68,182
-16,560
-20% -$81.1K 0.02% 841
2016
Q4 		$322K Sell
84,742
-33,705
-28% -$245K 0.02% 823
2016
Q3 		$1.06M Sell
118,447
-850
-0.7% -$7.11K 0.06% 346
2016
Q2 		$839K Buy
119,297
+104,297
+695% +$953K 0.05% 386
2016
Q1 		$108K Sell
15,000
-37,236
-71% -$366K 0.01% 663
2015
Q4 		$686K Buy
+52,236
New +$469K 0.05% 401

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFP Advisors's PACB Position: Q2 2026 in Review

IFP Advisors reduced its Pacific Biosciences (PACB) stake by 46% in Q2 2026, selling an estimated $23.4K and leaving 18,609 shares worth $31.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

IFP Advisors first reported a position in PACB in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.06M in Q3 2016. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • IFP Advisors held 18,609 shares of Pacific Biosciences worth $31.3K as of Q2 2026.
  • IFP Advisors sold 16,097 Pacific Biosciences shares in Q2 2026, an estimated $23.4K.
  • Pacific Biosciences made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2695 holding.
  • IFP Advisors first reported a position in Pacific Biosciences in Q4 2015 and has held it in 42 quarters since.
  • IFP Advisors's Pacific Biosciences position peaked at $1.06M in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.